Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB) is a small-molecule, orally active ago-allosteric modulator and agonist of the glucagon-like peptide-1 receptor (GLP-1R). Originally discovered by Novo Nordisk, DMB binds to an allosteric site on the GLP-1R, enhancing the binding affinity of endogenous GLP-1 while also directly stimulating cAMP production and glucose-dependent insulin secretion. In addition to its metabolic effects, DMB has been identified as a direct and selective gasdermin D (GSDMD) agonist that activates GSDMD pore formation and pyroptosis without requiring cleavage. This dual mechanism has led to preclinical research investigating DMB for the treatment of type 2 diabetes, obesity, transient focal cerebral ischemia (stroke), and as an immunotherapeutic agent to stimulate antitumor immunity in cancer.
- Other names
- 3-(tert-butylamino)-6,7-dichloro-2-(methylsulfonyl)quinoxaline6,7-dichloro-N-(1,1-dimethylethyl)-3-(methylsulfonyl)-2-quinoxalinamineGLP-1R agonist DMBGLP1R agonist DMBGLP 1R agonist DMBN-(tert-butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amineN-tert-butyl-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine
02
Targets
GSDMD (Gasdermin D)GLP1R (GLP-1R)
Beyond the preview
Go deeper on 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.